A Phase 4 interventional study of Ebicomb in Alzheimer Disease and Cognitive Change, sponsored by Neutec Ar-Ge San ve Tic A.Ş. Status unknown at 1 site in Turkey. Open to participants aged 55 Years to 90 Years. Per ClinicalTrials.gov, last updated 2022-05-17.
Sponsored by Neutec Ar-Ge San ve Tic A.Ş · Phase 4, Interventional, and Treatment
In this study, it is aimed to compare the effects of cognitive exercises applied on long-term internet environment to the cognitive level of patients who received donepezil, memantine or donepezil / memantin combination therapy.
3,965 studies on the registry are indexed under Alzheimer Disease; 926 are open to participants now.
This study's planned enrollment of 198 is above the median of 70 across 3,019 interventional studies indexed under Alzheimer Disease.
Browse Alzheimer Disease studies →Neutec Ar-Ge San ve Tic A.Ş is the lead sponsor of 20 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Donepezil/Memantin Combination
Combination Product: Ebicomb
Donepezil/Memantin Combination + Cognitive Exercises (BEYNEX Software)
Combination Product: Ebicomb
Donepezil Mono
Combination Product: Ebicomb
Donepezil Mono + Cognitive Exercises (BEYNEX Software)
Combination Product: Ebicomb
Memantine Mono
Combination Product: Ebicomb
Memantine Mono + Cognitive Exercises (BEYNEX Software)
Combination Product: Ebicomb
Combination product and combination product plus cognitive exercises will primarily be evaluated in this study
Also known as: Donepezil-Memantine
Change in MOCA total score
MOCA: Montreal - Cognitive Assessment
Time frame: 6-months
Change in GDS total score
GDS (The Geriatric Depression Scale)
Time frame: 6-months
Change in ADAS-Cog total score
ADAS-Cog: Alzheimer's Disease Assessment Scale- Cognitive Subscale
Time frame: 6-months
Change in CDR total score
CDR: The Clinical Dementia Rating
Time frame: 6-months
Change in B-ADL total score
B-ADL: The Bayer Activities of Daily Living Scale
Time frame: 6-months
Change in clock drawing test
The subject is asked to draw the face of a clock with all numbers and to set the hands for a specified time (hh:mm) and will be evaluated according to ability to draw.
Time frame: 6-months
Plan to share: Undecided
No publications or documents are linked to this record.
This study is status unknown, as verified in May 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Neutec Ar-Ge San ve Tic A.Ş